BRPI1009461A2 - método não invasivo para avaliar a progresão da fibrose hepática - Google Patents
método não invasivo para avaliar a progresão da fibrose hepáticaInfo
- Publication number
- BRPI1009461A2 BRPI1009461A2 BRPI1009461A BRPI1009461A BRPI1009461A2 BR PI1009461 A2 BRPI1009461 A2 BR PI1009461A2 BR PI1009461 A BRPI1009461 A BR PI1009461A BR PI1009461 A BRPI1009461 A BR PI1009461A BR PI1009461 A2 BRPI1009461 A2 BR PI1009461A2
- Authority
- BR
- Brazil
- Prior art keywords
- liver fibrosis
- noninvasive method
- fibrosis progression
- evaluate liver
- evaluate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4713—Plasma globulins, lactoglobulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7052—Fibrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16147409P | 2009-03-19 | 2009-03-19 | |
| US61/161,474 | 2009-03-19 | ||
| PCT/EP2010/053548 WO2010106140A1 (en) | 2009-03-19 | 2010-03-18 | Non-invasive method for assessing liver fibrosis progression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1009461A2 true BRPI1009461A2 (pt) | 2016-03-01 |
| BRPI1009461A8 BRPI1009461A8 (pt) | 2017-09-12 |
| BRPI1009461B1 BRPI1009461B1 (pt) | 2019-08-20 |
Family
ID=42227782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009461-0A BRPI1009461B1 (pt) | 2009-03-19 | 2010-03-18 | Métodos não invasivo para avaliar a progressão da fibrose hepática em um indivíduo e para avaliar se o indivíduo é formador de fibrose lenta, média ou rápida |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120010824A1 (pt) |
| EP (1) | EP2409154B1 (pt) |
| JP (1) | JP5612067B2 (pt) |
| CN (2) | CN107014996A (pt) |
| BR (1) | BRPI1009461B1 (pt) |
| ES (1) | ES2644725T3 (pt) |
| WO (1) | WO2010106140A1 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2815416A1 (en) * | 2010-10-21 | 2012-04-26 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
| US9036883B2 (en) * | 2011-01-10 | 2015-05-19 | The Regents Of The University Of Michigan | System and methods for detecting liver disease |
| JP6193225B2 (ja) * | 2011-06-29 | 2017-09-06 | インナー モンゴリア フルイ メディカル サイエンス カンパニー リミテッドInner Mongolia Furui Medical Science Co., Ltd | 肝線維症検出装置および検出システム |
| US9002656B2 (en) | 2011-10-17 | 2015-04-07 | Daxor Corporation | Automated total body albumin analyzer |
| EP2873017B1 (en) | 2012-07-11 | 2021-09-01 | University of Mississippi Medical Center | Method for the detection and staging of liver fibrosis from image acquired data |
| SG11201505294SA (en) * | 2013-01-08 | 2015-08-28 | Agency Science Tech & Res | A method and system for assessing fibrosis in a tissue |
| EP2772882A1 (en) * | 2013-03-01 | 2014-09-03 | Universite D'angers | Automatic measurement of lesions on medical images |
| EP2930515A1 (en) * | 2014-04-08 | 2015-10-14 | Universite D'angers | Prognostic tests for hepatic disorders |
| CN105092855B (zh) * | 2014-05-23 | 2017-10-03 | 杭州普望生物技术有限公司 | 一种用于肝纤维化和肝硬化检测的试剂盒 |
| EP2980753A1 (en) | 2014-08-01 | 2016-02-03 | Centre Hospitalier Universitaire d'Angers | Method for displaying easy-to-understand medical images |
| WO2016061621A1 (en) * | 2014-10-21 | 2016-04-28 | Jeffrey Gary Peter | Liver test |
| CN104887243B (zh) * | 2015-07-02 | 2017-08-01 | 郭璐 | 一种血小板指数测评快查计算滑动尺 |
| EP3491388B1 (en) * | 2016-08-01 | 2021-09-01 | Centre Hospitalier Universitaire d'Angers | Multi-targeted fibrosis tests |
| AU2018290511B2 (en) * | 2017-06-26 | 2022-01-27 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
| CN107368689B (zh) * | 2017-07-31 | 2019-11-19 | 董云鹏 | 人体数据采集和分析系统 |
| US12360113B2 (en) * | 2017-10-16 | 2025-07-15 | Biopredictive | Method of prognosis and follow up of primary liver cancer |
| CN110237263B (zh) * | 2018-03-07 | 2022-06-17 | 昆山新蕴达生物科技有限公司 | HFn包载阿霉素的方法及其产物 |
| CN108931645A (zh) * | 2018-07-26 | 2018-12-04 | 北京大学第医院 | 一种hcv清除后肝纤维化评估系统及评估方法 |
| CN109473175A (zh) * | 2018-11-07 | 2019-03-15 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种针对肝纤维化的非侵入性血清学评分模型及其设计方法 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| TWI685854B (zh) | 2019-02-01 | 2020-02-21 | 中國醫藥大學附設醫院 | 肝纖維化評估模型、肝纖維化評估系統及肝纖維化評估方法 |
| BR112021023622A2 (pt) * | 2019-05-24 | 2022-04-19 | Assembly Biosciences Inc | Composições farmaceuticas para o tratamento de hbv |
| CA3147038A1 (en) * | 2019-07-12 | 2021-01-21 | Primegen Biotech, Llc | Methods of treatment using encapsulated cells |
| CA3171882A1 (en) * | 2020-02-19 | 2021-08-26 | Hepion Pharmaceuticals, Inc. | Use of cyclosporine analogues for treating fibrosis |
| CN111783792B (zh) * | 2020-05-31 | 2023-11-28 | 浙江大学 | 一种提取b超图像显著纹理特征的方法及其应用 |
| CN112250769A (zh) * | 2020-09-30 | 2021-01-22 | 四川携光生物技术有限公司 | Ftcd和cyp2d6融合蛋白及其构建方法、应用 |
| US12523658B2 (en) | 2021-08-27 | 2026-01-13 | The Board Of Regents Of The University Of Texas System | Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications |
| JP2025538378A (ja) * | 2022-11-11 | 2025-11-28 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 長期的肝線維症進行を予測するための分子シグネチャー |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141380B2 (en) | 2000-04-28 | 2006-11-28 | Michael Volker | Assessment of liver fibrosis scoring with serum marker algorithms |
| US7668661B2 (en) * | 2000-04-28 | 2010-02-23 | Siemens Healthcare Diagnostics Inc. | Liver disease-related methods and systems |
| GB0202213D0 (en) | 2002-01-31 | 2002-03-20 | Imp College Innovations Ltd | Methods |
| US6986995B2 (en) | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
| WO2006129513A1 (ja) | 2005-05-30 | 2006-12-07 | Ajinomoto Co., Inc. | 肝疾患評価装置、肝疾患評価方法、肝疾患評価システム、肝疾患評価プログラムおよび記録媒体 |
| JP4575354B2 (ja) | 2003-01-14 | 2010-11-04 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 肝線維症測定用血清マーカー |
| WO2005025596A1 (en) * | 2003-09-16 | 2005-03-24 | Hadasit Medical Research Services & Development Ltd. | Glatiramer acetate for use as an immuno-modulatory agent |
| FR2870348B1 (fr) | 2004-05-14 | 2010-08-27 | Univ Angers | Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet |
| JP2008506369A (ja) | 2004-07-01 | 2008-03-06 | メディカル リサーチ ファンド オブ テル アヴィヴ ソラスキー メディカル センター | 慢性c型肝炎患者における肝臓線維化進行速度を予測するための方法およびキット |
| EP1626280B1 (en) * | 2004-08-12 | 2007-02-14 | Roche Diagnostics GmbH | Method for diagnosing liver fibrosis |
| DE602006019262D1 (de) * | 2005-08-11 | 2011-02-10 | Siemens Healthcare Diagnostics | QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN |
| CA2689654A1 (en) * | 2007-06-14 | 2008-12-18 | Vib Vzw | Diagnostic test for the detection of early stage liver cancer |
| US20100049029A1 (en) | 2008-08-20 | 2010-02-25 | Hong Kong Applied Science And Technology Research Institute Co., Ltd. | Piezoelectric magnetic resonance elastograph (mre) driver system |
-
2010
- 2010-03-18 BR BRPI1009461-0A patent/BRPI1009461B1/pt active IP Right Grant
- 2010-03-18 CN CN201610887218.2A patent/CN107014996A/zh active Pending
- 2010-03-18 CN CN201080021790.1A patent/CN102439456B/zh not_active Expired - Fee Related
- 2010-03-18 JP JP2012500256A patent/JP5612067B2/ja not_active Expired - Fee Related
- 2010-03-18 ES ES10712036.2T patent/ES2644725T3/es active Active
- 2010-03-18 US US13/257,456 patent/US20120010824A1/en not_active Abandoned
- 2010-03-18 WO PCT/EP2010/053548 patent/WO2010106140A1/en not_active Ceased
- 2010-03-18 EP EP10712036.2A patent/EP2409154B1/en active Active
-
2017
- 2017-05-30 US US15/608,287 patent/US10861582B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5612067B2 (ja) | 2014-10-22 |
| US20170337322A1 (en) | 2017-11-23 |
| WO2010106140A1 (en) | 2010-09-23 |
| BRPI1009461A8 (pt) | 2017-09-12 |
| EP2409154A1 (en) | 2012-01-25 |
| CN102439456A (zh) | 2012-05-02 |
| CN107014996A (zh) | 2017-08-04 |
| CN102439456B (zh) | 2016-11-02 |
| US10861582B2 (en) | 2020-12-08 |
| US20120010824A1 (en) | 2012-01-12 |
| JP2012520995A (ja) | 2012-09-10 |
| EP2409154B1 (en) | 2017-08-02 |
| ES2644725T3 (es) | 2017-11-30 |
| BRPI1009461B1 (pt) | 2019-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009461A2 (pt) | método não invasivo para avaliar a progresão da fibrose hepática | |
| PT2755675T (pt) | Composições de péptido semelhante a glucagão-2 e métodos para produzir e utilizar as mesmas | |
| BR112013009297A2 (pt) | conjunto para a construção de brinquedo | |
| BRPI0912106A2 (pt) | probióticos para melhorar a microbiota intestinal | |
| BRPI1007856A2 (pt) | braçadeira para cabos | |
| BRPI0919882A2 (pt) | métodos para avaliar padrões de rna | |
| ES2858225T8 (es) | Procedimiento para producir elementos estructurales templados | |
| BR112013018900A2 (pt) | conjuntos para uma estrutura | |
| BRPI1015147A2 (pt) | métodos para melhorar a farmacocinética | |
| BRPI1013482A2 (pt) | método para produzir um composto | |
| BR112013006876A2 (pt) | método para produzir uma composição de borracha | |
| BR112012031033A2 (pt) | composição de si--g-poliolefina e processo para fazer uma composição de si-g-poliolefina | |
| BR112013008317A2 (pt) | revestimento e método para produzir umrevestimento | |
| BRPI1011392A2 (pt) | nervura e processo para produzir uma nervura | |
| EP2414506A4 (en) | IMPROVED ENDOGLUCANASES | |
| BRPI0913136A2 (pt) | método para produzir uma peça e peça. | |
| BR112013014479A2 (pt) | método melhorado e kit para determinar a gravidade e progressão da doença periodontal | |
| BR112014013694A2 (pt) | método para tratar uma doença, e, kit | |
| BR112012011531A2 (pt) | método para produzir um tecido não tecido de fibra longa | |
| BR112012009097A2 (pt) | processo para produzir colagens | |
| BR112013009860A2 (pt) | conjunto para a construção de brinquedo | |
| BR112013009507A2 (pt) | conjunto para a construção de brinquedo | |
| BR112013015563A2 (pt) | método para produzir uma amina terciária | |
| BR112013005986A2 (pt) | processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo | |
| BR112012022525A2 (pt) | método para produzir butanol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS |